Literature DB >> 29848713

No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma.

Shintaro Shiba1, Kei Shibuya2, Hiroyuki Katoh3, Yoshinori Koyama4, Masahiko Okamoto2, Takanori Abe2, Tatsuya Ohno3, Takashi Nakano2.   

Abstract

BACKGROUND/AIM: The relationship between sarcopenia and prognosis in carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) has not yet been reported, therefore we analyzed the presence or absence of sarcopenia before C-ion RT as a prognostic factor for patients with HCC. PATIENTS AND METHODS: Data were retrospectively collected for patients who had undergone C-ion RT for HCC between September 2010 and December 2016. For defining the presence or absence of sarcopenia, skeletal muscles in the third lumbar vertebrae level were measured. Clinical outcomes were compared in the sarcopenia and non-sarcopenia groups.
RESULTS: Of the 68 patients who were analyzed, 22 were classified into the sarcopenia and 46 into the non-sarcopenia groups. Median follow-up of patients was 33.5 months. The three-year overall survival (OS) rates in the sarcopenia and non-sarcopenia groups were 66% and 77%, respectively (p=0.51).
CONCLUSION: Sarcopenia was not a prognostic factor for patients with HCC treated with C-ion RT, which was effective in HCC patients with sarcopenia without worsening the OS. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Carbon ion radiotherapy; hepatocellular carcinoma; sarcopenia

Mesh:

Year:  2018        PMID: 29848713     DOI: 10.21873/anticanres.12631

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes.

Authors:  Nezahat Muge Catikkas; Zumrut Bahat; Meryem Merve Oren; Gulistan Bahat
Journal:  Aging Clin Exp Res       Date:  2022-02-15       Impact factor: 4.481

2.  Prospective Observational Study of High-Dose Carbon-Ion Radiotherapy for Pelvic Recurrence of Rectal Cancer (GUNMA 0801).

Authors:  Shintaro Shiba; Masahiko Okamoto; Hiroki Kiyohara; Tatsuya Ohno; Takuya Kaminuma; Takayuki Asao; Hitoshi Ojima; Ken Shirabe; Hiroyuki Kuwano; Takashi Nakano
Journal:  Front Oncol       Date:  2019-07-31       Impact factor: 6.244

3.  Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.

Authors:  Yanqiao Ren; Yanyan Cao; Hong Ma; Xuefeng Kan; Chen Zhou; Jiacheng Liu; Qin Shi; Gansheng Feng; Bin Xiong; Chuansheng Zheng
Journal:  BMC Cancer       Date:  2019-10-22       Impact factor: 4.430

4.  Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report.

Authors:  Takeru Ohtaka; Shintaro Shiba; Kei Shibuya; Shohei Okazaki; Yuhei Miyasaka; Kento Tomizawa; Masahiko Okamoto; Tatsuya Ohno
Journal:  Clin J Gastroenterol       Date:  2022-06-09

5.  Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.

Authors:  Zheng Li; Qiang Li; Xiaohu Wang; Sha Li; Weiqiang Chen; Xiaodong Jin; Xinguo Liu; Zhongying Dai; Xiongxiong Liu; Xiaogang Zheng; Ping Li; Hui Zhang; Qiuning Zhang; Hongtao Luo; Ruifeng Liu
Journal:  Front Public Health       Date:  2021-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.